Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, talks on research investigating whether carfilzomib in combination with either lenalidomide and dexamethasone or thalidomide and dexamethasone overcomes the negative impact of high-risk cytogenetics in newly-diagnosed multiple myeloma (MM). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).